Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.75 |
| ▸ | GAA | P10253 | 3/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.75 |
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | ELANE | P08246 | 1/20 | 0.65 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 5/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9575455 | 0.93 | KDM4E (0.80) | SMN1; SMN2GAANPC1RAB9AKDM4E | |
| SCHEMBL31730773 | 0.93 | KDM4E (0.80) | SMN1; SMN2GAANPC1RAB9AKDM4E | |
| SCHEMBL14855964 | 0.92 | SMN1; SMN2 (0.80) | SMN1; SMN2GAANPC1RAB9AKDM4E | |
| SCHEMBL14855680 | 0.91 | KDM4E (0.76) | SMN1; SMN2GAAKDM4ELMNAALDH1A1 | |
| SCHEMBL14855679 | 0.89 | POLB (0.72) | SMN1; SMN2GAANPC1RAB9AKDM4E | |
| SCHEMBL4724997 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2GAANPC1RAB9AKDM4E | |
| SCHEMBL14856210 | 0.86 | KDM4E (0.69) | SMN1; SMN2GAAKDM4ELMNAALDH1A1 | |
| SCHEMBL10325817 | 0.85 | KDM4E (0.76) | SMN1; SMN2GAAKDM4ELMNAALDH1A1 | |
| SCHEMBL28026288 | 0.84 | KDM4E (0.66) | SMN1; SMN2GAANPC1RAB9AKDM4E | |
| SCHEMBL9183126 | 0.83 | ELANE (0.74) | SMN1; SMN2GAAKDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | claimed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | claimed |
| EP-2580190-A1 | NEW ANTIVIRAL COMPOUNDS | Wadell, Göran (SE) | 2013-04-17 | — | — | EP | claimed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | claimed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| EP-2580190-A1 | NEW ANTIVIRAL COMPOUNDS | Wadell, Göran (SE) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, EIF2AK2 | SMN1; SMN2 3366/4885GAA 487/4885NPC1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.